Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract - a preliminary report

Ming Huei Lee, M. T. Chen, K. K. Chen, Alex T L Lin, Y. H. Lee, L. M. Lee, Y. M. Chang, Luke S. Chang, J. M. Liu, R. K. Hsieh, P. M. Chen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The CMV (cisplatin, methotrexate, and vinblastine) and M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) regimens were used to treat 19 patients with advanced transitional-cell carcinoma (TCC) of the urothelial tract. In the CMV group, the partial response rate was 45.5% and the mean response duration was 6.3 months. No complete response was obtained in our series. The median duration of survival was 15.8 and 8.3 months in responders and nonresponders, respectively. The toxic symptoms included one case of sepsis and three cases of renal toxicity. However, nausea and vomiting were experienced by most patients and required the administration of antiemetics. In the M-VAC group, the median duration of survival for responders was longer than that of nonresponders (>10.2 vs 7.2 months), although the number of patients was too small for this difference to reach statistical significance. The toxic symptoms included one case of sepsis, two cases of renal toxicity, and nausea and vomiting in most patients. Bone metastasis in three patients did not respond to chemotherapy (CMV), a finding that is compatible with the results reported by other investigators. In summary, chemotherapy with the CMV or M-VAC regimen was effective in improving the response rate of patients. However, the duration of response was short, toxicity was severe in some cases, and the efficacy against bone lesions was poor. These problems must be solved to improve the outcome of patients with TCC following chemotherapy with the CMV or M-VAC regimens.

Original languageEnglish
JournalCancer Chemotherapy and Pharmacology
Volume30
Issue number1 Supplement
DOIs
Publication statusPublished - Jan 1992
Externally publishedYes

Fingerprint

Chemotherapy
Vinblastine
Transitional Cell Carcinoma
Urinary Tract
Methotrexate
Cisplatin
Cells
Drug Therapy
Doxorubicin
Toxicity
Therapeutics
Poisons
Nausea
Vomiting
Sepsis
Bone
Kidney
Bone and Bones
Antiemetics
Survival

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract - a preliminary report. / Lee, Ming Huei; Chen, M. T.; Chen, K. K.; Lin, Alex T L; Lee, Y. H.; Lee, L. M.; Chang, Y. M.; Chang, Luke S.; Liu, J. M.; Hsieh, R. K.; Chen, P. M.

In: Cancer Chemotherapy and Pharmacology, Vol. 30, No. 1 Supplement, 01.1992.

Research output: Contribution to journalArticle

Lee, MH, Chen, MT, Chen, KK, Lin, ATL, Lee, YH, Lee, LM, Chang, YM, Chang, LS, Liu, JM, Hsieh, RK & Chen, PM 1992, 'Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract - a preliminary report', Cancer Chemotherapy and Pharmacology, vol. 30, no. 1 Supplement. https://doi.org/10.1007/BF00686949
Lee, Ming Huei ; Chen, M. T. ; Chen, K. K. ; Lin, Alex T L ; Lee, Y. H. ; Lee, L. M. ; Chang, Y. M. ; Chang, Luke S. ; Liu, J. M. ; Hsieh, R. K. ; Chen, P. M. / Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract - a preliminary report. In: Cancer Chemotherapy and Pharmacology. 1992 ; Vol. 30, No. 1 Supplement.
@article{0b06edf9dce74137b0986e32eecd7369,
title = "Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract - a preliminary report",
abstract = "The CMV (cisplatin, methotrexate, and vinblastine) and M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) regimens were used to treat 19 patients with advanced transitional-cell carcinoma (TCC) of the urothelial tract. In the CMV group, the partial response rate was 45.5{\%} and the mean response duration was 6.3 months. No complete response was obtained in our series. The median duration of survival was 15.8 and 8.3 months in responders and nonresponders, respectively. The toxic symptoms included one case of sepsis and three cases of renal toxicity. However, nausea and vomiting were experienced by most patients and required the administration of antiemetics. In the M-VAC group, the median duration of survival for responders was longer than that of nonresponders (>10.2 vs 7.2 months), although the number of patients was too small for this difference to reach statistical significance. The toxic symptoms included one case of sepsis, two cases of renal toxicity, and nausea and vomiting in most patients. Bone metastasis in three patients did not respond to chemotherapy (CMV), a finding that is compatible with the results reported by other investigators. In summary, chemotherapy with the CMV or M-VAC regimen was effective in improving the response rate of patients. However, the duration of response was short, toxicity was severe in some cases, and the efficacy against bone lesions was poor. These problems must be solved to improve the outcome of patients with TCC following chemotherapy with the CMV or M-VAC regimens.",
author = "Lee, {Ming Huei} and Chen, {M. T.} and Chen, {K. K.} and Lin, {Alex T L} and Lee, {Y. H.} and Lee, {L. M.} and Chang, {Y. M.} and Chang, {Luke S.} and Liu, {J. M.} and Hsieh, {R. K.} and Chen, {P. M.}",
year = "1992",
month = "1",
doi = "10.1007/BF00686949",
language = "English",
volume = "30",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1 Supplement",

}

TY - JOUR

T1 - Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract - a preliminary report

AU - Lee, Ming Huei

AU - Chen, M. T.

AU - Chen, K. K.

AU - Lin, Alex T L

AU - Lee, Y. H.

AU - Lee, L. M.

AU - Chang, Y. M.

AU - Chang, Luke S.

AU - Liu, J. M.

AU - Hsieh, R. K.

AU - Chen, P. M.

PY - 1992/1

Y1 - 1992/1

N2 - The CMV (cisplatin, methotrexate, and vinblastine) and M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) regimens were used to treat 19 patients with advanced transitional-cell carcinoma (TCC) of the urothelial tract. In the CMV group, the partial response rate was 45.5% and the mean response duration was 6.3 months. No complete response was obtained in our series. The median duration of survival was 15.8 and 8.3 months in responders and nonresponders, respectively. The toxic symptoms included one case of sepsis and three cases of renal toxicity. However, nausea and vomiting were experienced by most patients and required the administration of antiemetics. In the M-VAC group, the median duration of survival for responders was longer than that of nonresponders (>10.2 vs 7.2 months), although the number of patients was too small for this difference to reach statistical significance. The toxic symptoms included one case of sepsis, two cases of renal toxicity, and nausea and vomiting in most patients. Bone metastasis in three patients did not respond to chemotherapy (CMV), a finding that is compatible with the results reported by other investigators. In summary, chemotherapy with the CMV or M-VAC regimen was effective in improving the response rate of patients. However, the duration of response was short, toxicity was severe in some cases, and the efficacy against bone lesions was poor. These problems must be solved to improve the outcome of patients with TCC following chemotherapy with the CMV or M-VAC regimens.

AB - The CMV (cisplatin, methotrexate, and vinblastine) and M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) regimens were used to treat 19 patients with advanced transitional-cell carcinoma (TCC) of the urothelial tract. In the CMV group, the partial response rate was 45.5% and the mean response duration was 6.3 months. No complete response was obtained in our series. The median duration of survival was 15.8 and 8.3 months in responders and nonresponders, respectively. The toxic symptoms included one case of sepsis and three cases of renal toxicity. However, nausea and vomiting were experienced by most patients and required the administration of antiemetics. In the M-VAC group, the median duration of survival for responders was longer than that of nonresponders (>10.2 vs 7.2 months), although the number of patients was too small for this difference to reach statistical significance. The toxic symptoms included one case of sepsis, two cases of renal toxicity, and nausea and vomiting in most patients. Bone metastasis in three patients did not respond to chemotherapy (CMV), a finding that is compatible with the results reported by other investigators. In summary, chemotherapy with the CMV or M-VAC regimen was effective in improving the response rate of patients. However, the duration of response was short, toxicity was severe in some cases, and the efficacy against bone lesions was poor. These problems must be solved to improve the outcome of patients with TCC following chemotherapy with the CMV or M-VAC regimens.

UR - http://www.scopus.com/inward/record.url?scp=0026761592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026761592&partnerID=8YFLogxK

U2 - 10.1007/BF00686949

DO - 10.1007/BF00686949

M3 - Article

C2 - 1394825

AN - SCOPUS:0026761592

VL - 30

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1 Supplement

ER -